桃红四物汤联合莫西沙星对慢性盆腔炎患者血清炎症因子和血液流变学及安全性评价

Effect and safety of Taohong Siwu decoction combined with moxifloxacin in treatment of chronic pelvic inflammatory disease and its impact on serum inflammatory factors and hemorheology

目的 观察桃红四物汤联合莫西沙星对盆腔炎性疾病后遗症患者血清炎症因子、血液流变学的影响及安全性评价。方法 将本院妇产科2015年3月至2017年3月收治的130例盆腔炎性疾病后遗症患者随机(乱数表法)分为两组:A组和B组,每组65例,A组患者给予莫西沙星片治疗,B组在A组的基础上加用桃红四物汤,两组患者疗程均为15d。观察记录患者的临床疗效,检测治疗前后血清中白介素-6(IL-6)、白介素-10(IL-10)、C-反应蛋白(CRP)等血清炎症因子的变化,检测低切全血黏度、高切全血黏度、血浆黏度和纤维蛋白原(FIB)等血液流变学指标的变化,同时记录研究过程中患者的所有不良反应。结果 B组总有效率高于A组(90.77%比69.23%),差异有统计学意义(P<0.05);经过治疗后,IL-6、IL-10、CRP均明显下降(均P<0.05),且B组与A组相比,各指标下降得更显著(均P<0.05);低切全血黏度、高切全血黏度、血浆粘度、FIB均明显下降(均P<0.05),且B组与A组相比,各指标下降得更显著(均P<0.05);两组不良反应发生率比较差异无统计学意义(P>0.05)。结论 桃红四物汤联合莫西沙星对盆腔炎性疾病后遗症的治疗具有更好的疗效,该方法可以降低患者血清炎症因子,改善患者血液流变学改变,是一种治疗盆腔炎性疾病后遗症的优化选择,值得临床参考应用。

Objective To study the effect and safety of Taohong Siwu decoction combined with moxifloxacin in the treatment of sequelae of pelvic inflammatory disease and its impact on inflammatory factors and hemorheology. Methods 130 cases of sequelae of pelvic inflammatory disease treated at our hospital from March, 2015 to March, 2017 were randomly divided into group A and group B. Group A was treated with moxifloxacin, and the group B with Taohong Siwu decoction and moxifloxacin, for 15 d. After the treatment, the clinical efficacy were analyzed. The levels of serum inflammatory factors such as interleukin-6 (IL-6), interleukin-10 (IL-10), and C-reactive protein (CRP) were detected before and after the treatment. The changes of low shear blood viscosity, high blood viscosity, plasma viscosity, and fibrinogen (FIB) before and after the treatment were detected. All the adverse reactions were recorded during the study. Results After the treatment, the total efficacy was significantly higher in group B than in group A (90.77% vs. 69.23%, P < 0.05). After treatment, The levels of IL-6, IL-10, and CRP as well as low shear blood viscosity, high blood viscosity, plasma viscosity, and FIB were significantly lower after than before the treatment in both groups (all P < 0.05), and were lower in group B than in group A after the treatment (all P < 0.05). There was no statistical difference in the incidence of adverse reactions between the two groups (P > 0.05). Conclusion Taohong Siwu decoction combined with moxifloxacin for sequelae of pelvic inflammatory disease is effective, and can reduce serum inflammatory factors and improve hemorheological changes, so it is an optimal choice for sequelae of pelvic inflammatory disease and is worth for clinical application.